Back

121
Star analysis of value for money for use of oral anticoagulants by quality-adjusted life gain

EP Europace Journal

10 October 2018
Organised by: Logo
Read full article
ESC Journals

Contributors

A Orlowski
A Orlowski

Author

J Wilkins
J Wilkins

Author

R Ashton
R Ashton

Author

R Glover
R Glover

Author

You may be interested in
thumbnail
Congress Presentation
Cost-effectiveness of direct oral anticoagulants for cancer-associated venous thromboembolism
3 September 2019
thumbnail
Congress Presentation
Impact of proton pump inhibitor on quality of anticoagulant control and outcomes in atrial fibrillation patients treated with an oral anticoagulant in the COOL-AF registry.
28 August 2023
thumbnail
Congress Presentation
Symptom burden, coagulopathy and heart disease, and quality of life at baseline and after 1-year follow-up following acute SARS-CoV-2 infection in a community medicine setting
28 August 2023
thumbnail
Congress Presentation
Budget impact analysis of antiplatelet therapy with cangrelor in patients with acute coronary artery disease undergoing percutaneous coronary intervention in Belgium
13 March 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources